Russian government to double the volume of localized APIs within next five years

22 October 2025

The Russian government plans to double the volume of localized active pharmaceutical ingredients (APIs) within the next five years, that will ensure Russia’s state security in the field of pharmaceutics.

This has been recently announced by Anton Alikhanov, Russia’s Minister of Industry and Trade, who is a state official personally responsible for the development of pharmaceutical sector in the Russian government.

He said during the recent Bioprom forum that, as one of Russia’s most important events in the field of pharmaceutics, as of now, Russia has almost completely localized the production of drugs from the list of vital and essential, while the same plans are in case of active ingredients. According to the Minister, the volume of their production in Russia will be doubled within the next 5 years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight



More Features in Generics